Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $44.00 → $57.00 | Buy → Neutral | BofA Securities |
| 8/2/2024 | $26.00 → $39.00 | Underweight → Equal Weight | Barclays |
| 1/3/2024 | $33.00 | Underweight | Barclays |
| 11/3/2023 | $39.00 → $28.00 | Underweight → Equal Weight | Wells Fargo |
| 11/3/2023 | Buy → Neutral | BTIG Research | |
| 11/3/2023 | $70.00 → $39.00 | Neutral → Overweight | Piper Sandler |
| 10/11/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 9/26/2023 | $56.00 → $39.00 | Underweight | Wells Fargo |
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024. "We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year," stated Randall Lipps, ch
Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the fourth quarter and full year 2024, before market open on Thursday, February 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 2515873. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-pr
Omnicell delivers solid third quarter financial results Total revenues of $282 million GAAP net income per diluted share of $0.19 Non-GAAP net income per diluted share of $0.56 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its third quarter ended September 30, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased to deliver another consecutive quarter of solid financial performance, with results within or exceeding each of ou
BofA Securities downgraded Omnicell from Buy to Neutral and set a new price target of $57.00 from $44.00 previously
Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously
Barclays initiated coverage of Omnicell with a rating of Underweight and set a new price target of $33.00
4 - OMNICELL, INC. (0000926326) (Issuer)
4 - OMNICELL, INC. (0000926326) (Issuer)
4 - OMNICELL, INC. (0000926326) (Issuer)
Medical device, pharmaceutical, and life sciences expert tapped to lead Company's technology strategy and global engineering organization Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250324514095/en/Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, on March 31, 2025. Dr. Genova will lead Omnicell's technology str
Company Reiterates First Quarter and Full Year 2025 Guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced that Nchacha Etta will be stepping down from his role as Executive Vice President and Chief Financial Officer, effective September 15, 2025 or until a successor is named. Mr. Etta will continue to serve as Executive Vice President and Chief Financial Officer while Omnicell searches for a new Chief Financial Officer and will work to ensure a smooth transition of his role and responsibilities. The Company has commenced a national search for his successor
Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024. "We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year," stated Randall Lipps, ch
The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024
FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me
Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e
8-K - OMNICELL, INC. (0000926326) (Filer)
8-K - OMNICELL, INC. (0000926326) (Filer)
10-K - OMNICELL, INC. (0000926326) (Filer)